Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC

This is a single-arm, open-lable exploratory study of Lurbinectedin in combination with Serplulimab as maintenance therapy in participants with extensive-stage small-cell lung cancer (ES-SCLC) after first-line induction therapy with carboplatin, etoposide, and Serplulimab. The study consists of 2 phases: an induction phase and a maintenance phase. Participants need to have an ongoing response or stable disease per the Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 criteria after completion of 4 cycles of carboplatin, etoposide, and Serplulimab induction treatment in order to be cons

Trial Details

NCT ID
NCT06497530
Phase
PHASE2
Sponsor
Guangzhou Institute of Respiratory Disease
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Serplulimab
  • Lurbinectedin
  • Carboplatin
  • Etoposide
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Fully informed about the study and voluntarily signed a written informed consent form, and able to comply with the requirements and restrictions li…
  • Male or female with age ≥ 18 years;
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1;
  • Histologically or cytologically confirmed diagnosis of extensive-stage small cell lung cancer (ES-SCLC) and has not received any systemic treatment…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →